Prognostic analysis of hidradenocarcinoma: a SEER-based observational study

Teng Gao, Sheng Pan, Meng Li and Runping Su

Department of Dermatology, Changzhou Geriatric Hospital Affiliated to Soochow University, Changzhou No.7 People’s Hospital, Changzhou, China; Department of Neurology, Changzhou Geriatric Hospital Affiliated to Soochow University, Changzhou No.7 People’s Hospital, Changzhou, China

ABSTRACT

Background: Hidradenocarcinoma is a rare malignancy of sweat gland differentiation. Published literature has reported that hidradenocarcinoma has a high recurrence and metastasis rate, and the prognosis is extremely poor. However, the sample sizes included in these studies are insufficient, and therefore, the findings are doubtful.

Materials and methods: Clinicopathological characteristics and survival data of 289 hidradenocarcinoma patients were extracted from the SEER database (covering 18 registries, 2000–2018) released in July 2021. The distribution of clinicopathological characteristics was compared using the Pearson chi-square test. Overall survival (OS) and cancer-specific survival (CSS) were analysed using the log-rank test and univariate analysis.

Results: The primary site of hidradenocarcinoma in 121 patients was located in the head and neck, accounting for 41.9%, and the others were located in the trunk and limbs. For hidradenocarcinoma, the mean OS and CSS were 164 months and 165.9 months, respectively; the 10-year OS rate and CSS rate were 60.2% and 90.5%, respectively. Survival analysis showed that the primary site, sex, age, race, histologic grade, stage, and surgery are not associated with hidradenocarcinoma patients’ OS or CSS. For head and neck hidradenocarcinoma or trunk and limbs hidradenocarcinoma, sex, age, race, histologic grade, AJCC stage, and primary site surgery are still not related to prognosis. Tumour size is correlated with patients’ OS rather than CSS.

Conclusions: Hidradenocarcinoma is a malignant tumour with a good prognosis, which is different from previous views. Tumour size is inversely proportional to patients’ overall survival time affecting the OS and CSS of patients. Improving health awareness, initial histological examination and timely surgery are the keys to improving the prognosis.

Abbreviations: SEER: Surveillance, Epidemiological and End Results; AJCC: American Joint Committee on Cancer; OS: overall survival; CSS: cancer-specific survival; HRs: hazard ratios; CIs: confidence intervals.

Background

In 1954, Keasby and Hadley first reported that hidradenocarcinoma was believed to be an uncommon malignant transformation of nodular hidradenoma [1]. As an uncommon malignant transformation, hidradenocarcinoma was found in 1:13,000 skin biopsies, accounting for only 6% of malignant eccrine tumours [2,3]. The study by Kazakov et al. [4] showed that a hidradenoma remnant was found in 5 of 14 primary hidradenocarcinomas, and the transition to a cancerous component was clearly evident. Hidradenocarcinoma is also known as malignant clear cell hidradenoma, clear cell hidradenocarcinoma, and malignant acrosyringoma [5,6]. The main clinical manifestations of hidradenocarcinoma are isolated, hard, asymptomatic intradermal erythematous, or violaceous nodules on the head, neck, trunk, limbs, or oral cavity [7]. The accepted histological criteria for diagnosing hidradenocarcinoma include lack of demarcation, invasive growth pattern, deep extension, nuclear pleomorphism, necrosis, vascular invasion, perineural invasion, and the presence of an increased number of mitoses [8–10]. Hidradenocarcinoma usually grows slowly for many years, but it may increase rapidly in the short term [11].

At present, there are only a few clinical studies about hidradenocarcinoma [12–15]. In these studies with limited case numbers and follow-up, an aggressive clinical course characterised by local recurrence...
and systemic metastases is frequently observed [1, 4, 15–17]. The study conducted by Souvatzidis et al. reported a series of 7 hidradenocarcinoma patients and observed their clinicopathological characteristics and biological manifestations [15]. They concluded that hidradenocarcinoma has a high recurrence and metastasis rate, and the prognosis is extremely poor. Nazarian et al. [16] followed up 8 hidradenocarcinoma patients (range 2 months to 3 years, median 1 year and 5 months). Multiple regional lymph nodes and skin metastases were observed in 2 patients at 8 months and 3 years after resection, respectively. Kazakov et al. [4] followed 12 hidradenocarcinoma patients (range 4 months to 11 years, median 3.5 years). Two patients died of multiple visceral metastases at 4 months and 5 months after diagnosis, respectively. Of the remaining 10 surviving patients, a local recurrence was observed in 3 patients of whom one experienced 2 local recurrences. To better assess the prognosis of hidradenocarcinoma, we conducted a systematic analysis of the hidradenocarcinoma data in the Surveillance, Epidemiological and End Results (SEER) database.

**Materials and methods**

**Data retrieval**

This research was approved by the Ethical Committee of Soochow University and followed the guidelines outlined in the Declaration of Helsinki. After obtaining the research permission (serial number: 14414-Nov2020), we used SEER Stat version 8.3.9.1 to retrieve the SEER database (covering 18 registries, 2000–2018) released in July 2021. Because patient data come from a public database, informed consent was not required.

The selection variables were histological type (ICD–0–3) for malignant nodular hidradenoma (8402/3) and site recode (ICD–0–3/WHO2008) for other nonepithelial skin diseases. Patients with any other malignant tumours were excluded. The following variables were extracted from the database: cause of death, follow-up, sex, age, race, tumour size, histologic grade (ICD–0–2), American Joint Committee on Cancer (AJCC) stage, and primary site surgery.

**Statistical analysis**

Except for survival data, other data were converted into categorical variables and compared with the Pearson chi-square test. Overall survival (OS) and cancer-specific survival (CSS) were derived from the cause of death provided by the SEER. The precise cut-off was defined according to the sensitivity, specificity and Youden Index [18]. The relationship between survival and follow-up was depicted as a Kaplan–Meier curve, and curves were compared using the log-rank test. Univariate analysis was used to screen the prognostic risk factors for hidradenocarcinoma, expressed in hazard ratios (HRs) and 95% confidence intervals (CIs). Multivariate analysis will be performed only when there is more than one variable with statistical significance (p < .05) in univariate analysis. When the P value was less than .05, the difference was considered to be statistically significant. SPSS version 22.0 statistical package (IBM, NY) and GraphPad Prism 8 (San Diego, California) was used for statistical analysis.

**Results**

**Clinicopathological characteristics**

Information on 289 hidradenocarcinoma patients was extracted from the SEER database, of which 170 were males, accounting for 58.8%. The mean age was 62.5 years (range 15–89 years). Table 1 summarises the distribution of the main characteristics. The incidence increased with age, with 60.6% of patients aged 60 years or older. White people account for the majority, while people of colour account for only 20.1%. The tumour size, histologic grade, and AJCC stage of many included patients are unknown. In patients with definite tumour size, the mean tumour size was 27.3 mm (range from 4 mm to 125 mm), the precise cut-off of tumour size for OS was 2.8 cm, and the precise cut-off of tumour size for CSS was 3.95 cm. In patients with known lymph node stage, the lymph node metastasis rate was 4.3% (10 of 235). In patients with known metastasis stage, the distant metastasis rate was 2.4% (6 of 248). Of the 6 patients with distant metastases, one had multiple bones and lung metastases, two had multiple brain and lung metastases, two had isolated lung metastases, and one had other (distant metastases, but none to bone, brain, liver, lung, and distant lymph node). The proportion of well-differentiated and moderately differentiated patients was nearly three times that of poorly differentiated and undifferentiated patients (21.1% versus 7.6%). The proportion of stage I–II patients (42.9%) was significantly higher than that of stage III–IV patients (6.6%). Only six patients (2.1%) had distant metastases at the time of diagnosis. A total of 90.3% of patients underwent primary site surgery after diagnosis.

According to the primary site, we compared the patients into two groups: the head and neck and the
trunk and limbs. The primary site of hidradenocarcinoma in 121 patients was located in the head and neck, accounting for 41.9%, and the others were located in the trunk and limbs. Table 1 shows the differences in the distribution of characteristics of patients with different primary sites. The results indicated that there was no significant difference in the distribution of sex, age, race, tumour size, histologic grade, AJCC stage, or primary site surgery between the two groups ($P > .05$).

### Survival analysis

For all hidradenocarcinoma patients, the median follow-up time was 58 months. At the end of the follow-up, 84 patients died, of which 15 patients died of hidradenocarcinoma. The 1-year, 3-year, 5-year, and 10-year OS rates of these patients were 92.8%, 84.5%, 75.9%, and 60.2%, respectively (Table 2; Figure 1A). The mean and median OS was 122.8 months and 164 months, respectively (Table 2). The 1-year, 3-year, 5-year, and 10-year CSS rates of these patients were 98.2%, 97.2%, 93.8%, and 90.5%, respectively (Table 2; Figure 1A). The mean CSS was 165.9 months (Table 2).

For head and neck hidradenocarcinoma, the median follow-up time was 52 months. At the end of the follow-up, 38 patients died, of which 7 patients died of hidradenocarcinoma. The 1-year, 3-year, 5-year, and 10-year OS rates of these patients were 91.3%, 83.4%, 72.6%, and 54.1%, respectively (Table 2). The mean OS was 117 months (Table 2). The 1-year, 3-year, 5-year, and 10-year CSS rates of these patients were 97.3%, 96.1%, 93.1%, and 89.2%, respectively (Table 2). The mean CSS was 163.9 months (Table 2).

For trunk and limbs hidradenocarcinoma, the median follow-up time was 62.5 months. At the end of the follow-up, 46 patients died, of which 8 patients

### Table 1. The distribution of the main clinicopathological characteristics of hidradenocarcinoma patients.

| Variables          | Number of patients | Head and neck | Trunk and limbs | $\chi^2$ | $P$ value |
|--------------------|--------------------|---------------|-----------------|---------|-----------|
| Sex                |                    |               |                 |         |           |
| Male               | 170 (58.8%)        | 78 (64.5%)    | 92 (54.8%)      | 2.733   | .098      |
| Female             | 119 (41.2%)        | 43 (35.5%)    | 76 (45.2%)      |         |           |
| Age                |                    |               |                 |         |           |
| 0–29 years         | 12 (4.2%)          | 5 (4.1%)      | 7 (4.2%)        | 2.083   | .353      |
| 30–59 years        | 102 (33.5%)        | 37 (30.6%)    | 102 (35.3%)     |         |           |
| ≥60 years          | 175 (60.6%)        | 79 (65.3%)    | 175 (60.6%)     |         |           |
| Race               |                    |               |                 |         |           |
| White              | 231 (79.9%)        | 98 (81.0%)    | 133 (79.2%)     | 0.146   | .702      |
| Others             | 58 (20.1%)         | 23 (19.0%)    | 35 (20.8%)      |         |           |
| Tumour size        |                    |               |                 |         |           |
| 1–10 mm            | 47 (16.3%)         | 25 (20.7%)    | 22 (13.1%)      | 5.857   | .439      |
| 11–20 mm           | 36 (12.5%)         | 17 (14.0%)    | 19 (11.3%)      |         |           |
| 21–30 mm           | 24 (8.3%)          | 9 (7.4%)      | 15 (8.9%)       |         |           |
| 31–40 mm           | 23 (8.0%)          | 7 (5.8%)      | 16 (9.5%)       |         |           |
| 41–50 mm           | 15 (5.2%)          | 5 (4.1%)      | 10 (6.0%)       |         |           |
| ≥50 mm             | 17 (5.9%)          | 5 (4.1%)      | 12 (7.1%)       |         |           |
| Grade              |                    |               |                 |         |           |
| I–II               | 61 (21.1%)         | 27 (22.3%)    | 34 (20.2%)      | 0.361   | .835      |
| III–IV             | 22 (7.6%)          | 10 (8.3%)     | 12 (7.1%)       |         |           |
| Unknown            | 206 (71.3%)        | 84 (69.4%)    | 122 (72.6%)     |         |           |
| AJCC stage         |                    |               |                 |         |           |
| I–II               | 124 (42.9%)        | 54 (44.6%)    | 70 (41.7%)      | 0.655   | .721      |
| III–IV             | 19 (6.6%)          | 9 (7.4%)      | 10 (6.4%)       |         |           |
| Unknown            | 146 (50.5%)        | 58 (47.9%)    | 88 (52.4%)      |         |           |
| T stage            |                    |               |                 |         |           |
| T1–2               | 131 (45.3%)        | 52 (43.0%)    | 79 (47.0%)      | 4.879   | .087      |
| T3–4               | 18 (6.2%)          | 12 (9.9%)     | 6 (3.6%)        |         |           |
| Unknown            | 140 (48.4%)        | 57 (47.1%)    | 83 (49.4%)      |         |           |
| N stage            |                    |               |                 |         |           |
| N0                 | 225 (77.9%)        | 97 (80.2%)    | 128 (76.2%)     | 0.918   | .632      |
| N1–2               | 10 (3.5%)          | 3 (2.5%)      | 7 (4.2%)        |         |           |
| Unknown            | 54 (18.7%)         | 21 (17.4%)    | 33 (19.6%)      |         |           |
| M stage            |                    |               |                 |         |           |
| M0                 | 242 (83.7%)        | 102 (84.3%)   | 140 (83.3%)     | 0.190   | .909      |
| M1                 | 6 (2.1%)           | 2 (1.7%)      | 4 (2.4%)        |         |           |
| Unknown            | 41 (14.2%)         | 17 (14.0%)    | 24 (14.3%)      |         |           |
| Primary site surgery |                  |               |                 |         |           |
| Performed          | 261 (90.3%)        | 107 (88.4%)   | 154 (91.7%)     | 0.842   | .359      |
| Unperformed        | 28 (9.7%)          | 14 (11.6%)    | 14 (8.3%)       |         |           |

AJCC: American Joint Committee on Cancer; T: Tumour; N: Node; M: Metastasis.
died of hidradenocarcinoma. The 1-year, 3-year, 5-year, and 10-year OS rates of these patients were 93.8%, 85.2%, 78.1%, and 64.5%, respectively (Table 2). The mean and median OS were 125 months and 164 months, respectively (Table 2). The 1-year, 3-year, 5-year, and 10-year CSS rates of these patients were 98.7%, 97.9%, 94.4%, and 91.7%, respectively (Table 2). The mean CSS was 162.7 months (Table 2).

The log-rank test results showed that the primary site of hidradenocarcinoma was not a factor that affected patient OS ($p = .191$) or CSS ($p = .559$) (Table 2; Figure 1B). In addition, log-rank tests based on sex, race, histologic grade, AJCC stage, and primary site surgery also showed similar results ($P > .05$; Figure 2 and 3). However, tumour size is a factor that is related to the patient’s prognosis. Hidradenocarcinoma patients with larger tumour sizes had worse OS ($p = .002$; Figure 4) and CSS ($P < .001$; Figure 4). Age appeared to be a factor related to patient OS ($P < .001$; Figure 4), but it was not related to patient CSS ($p = .382$; Figure 4).

The results of the univariate analysis showed that the primary site, sex, age, race, histologic grade, AJCC stage, and primary site surgery were not associated with patient OS or CSS ($P > .05$; Table 3). Tumour size was a factor related to the patient OS rather than CSS (Table 3), which was inconsistent with the log-rank test results. The patients were further grouped according to the primary site for univariate analysis. The results show that for head and neck hidradenocarcinoma or trunk and limbs hidradenocarcinoma, sex, age, race, histologic grade, AJCC stage, and primary site surgery were still not related to prognosis ($P > .05$; Table 4). Tumour size was still a factor related to the patient OS rather than CSS (Table 4).

**Discussion**

In this study, we included 289 hidradenocarcinoma patients from the SEER database diagnosed between 2000 and 2018. This is currently the largest study on the clinicopathological features and prognosis of hidradenocarcinoma. Considering the differences in the extent of surgical resection of hidradenocarcinomas in the head and neck and other sites, we divided the population into two groups: head and neck hidradenocarcinoma and trunk and limbs hidradenocarcinoma for comparison. The results showed that there were no significant differences between the two groups in clinicopathological features and prognosis. However, the incidence of hidradenocarcinoma is higher in the elderly. In addition, if unknown patients

---

**Table 2.** Survival rates of hidradenocarcinoma patients stratified by primary site.

| Variables          | All patients | Head and neck | Trunk and limbs | $P$ value |
|--------------------|--------------|---------------|-----------------|-----------|
| Overall survival   |              |               |                 |           |
| 1-year OS rate (95%CI) | 92.8% (89.7%–95.9%) | 91.3% (86.2%–96.4%) | 93.8% (90.1%–97.5%) | .191      |
| 3-year OS rate (95%CI) | 84.5% (79%–90%) | 83.4% (76.3%–90.5%) | 85.2% (79.5%–90.9%) |           |
| 5-year OS rate (95%CI) | 75.9% (70.4%–81.4%) | 72.6% (63.6%–81.6%) | 78.1% (71.2%–85%) |           |
| 10-year OS rate (95%CI) | 60.2% (52.6%–67.8%) | 54.1% (41.9%–66.3%) | 64.5% (54.9%–74.1%) |           |
| Mean OS (months)   | 122.8        | 117           | 125             |           |
| Median OS (months) | 164          | –             | 164             | .559      |
| Cancer-specific survival |            |               |                 |           |
| 1-year CSS rate (95%CI) | 98.2% (96.6%–99.8%) | 97.3% (94.4%–100%) | 98.7% (96.9%–100%) |           |
| 3-year CSS rate (95%CI) | 97.2% (95.9%–99.4%) | 96.1% (92.2%–100%) | 97.9% (95.5%–100%) |           |
| 5-year CSS rate (95%CI) | 93.8% (90.5%–97.1%) | 93.1% (87.6%–98.6%) | 94.4% (90.3%–98.5%) |           |
| 10-year CSS rate (95%CI) | 90.5% (85%–96%) | 89.2% (80%–94.4%) | 91.7% (85.2%–98.2%) |           |
| Mean CSS (months)   | 165.9        | 163.9         | 162.7           |           |
| Median CSS (months) | –            | –             | –               |           |

OS: overall survival; CSS: cancer-specific survival; CI: confidence interval.
were excluded, it could be seen that most hidradenocarcinomas had good histologic grades (I–II) and AJCC stages (I–II) at the time of diagnosis.

Previous studies have concluded that hidradenocarcinoma has high rates of recurrence and metastasis, resulting in an unfavourable prognosis [15,19]. However, our research results show that the 10-year OS rate and CSS rate of hidradenocarcinoma reach 60.2% and 90.5%, respectively. Compared with most other malignant tumours, hidradenocarcinoma has a great advantage in prognosis. The OS rate of hidradenocarcinoma is worse than the CSS rate due to the high proportion of elderly patients leading to more noncancer deaths. The recurrence-free survival rate cannot be assessed due to the lack of relevant data in the SEER database. In addition, 248 included patients had a clear AJCC M stage, of which only six patients had distant metastases, accounting for 2.4%. Hidradenocarcinoma does not have a high rate of metastasis, as reported by Souvatzidis et al. [15].

Although there are generally accepted histological criteria for the diagnosis of hidradenocarcinoma [8–10], some lesions do not meet all criteria. In addition, atypical hidradenomas have some focal atypical features, including lack of circumscription, nuclear pleomorphism, focal necrosis, and prominent mitotic activity [10]. Hyaloid stroma, duct formation, clear cell change, epidermoid morphology, nuclear pseudo inclusion, and nuclear groove can be observed in most atypical hidradenomas and hidradenocarcinomas [16]. Therefore, the differential diagnosis of hidradenocarcinoma is challenging. Nazarian et al. [16] compared the histological appearance of 15 atypical hidradenomas and 15 hidradenocarcinomas and proposed some distinguishing histological features of hidradenocarcinoma, including invasive growth pattern, deep extension, necrosis, nuclear pleomorphism, and ≥ 4 mitoses per 10 high-power fields. Furthermore, they detected the molecular biological
Figure 3. Cancer-specific survival (CSS) of hidradenocarcinoma patients stratified by sex, race, histologic grade, American Joint Committee on Cancer (AJCC) stage, and primary site surgery.

Figure 4. Overall survival (OS) and cancer-specific survival (CSS) of hidradenocarcinoma patients stratified by tumour size and age.
alterations and found that lesions with Ki-67 > 11% and/or PHH3 > 0.7% would likely be malignant, and Her2/neu was rarely overexpressed in hidradenocarcinomas. Kazakov et al. [4] demonstrated that hidradenocarcinomas exhibit some microscopic heterogeneity, which can be classified into low-grade and high-grade. High-grade hidradenocarcinomas are histologically similar to hidradenomas. They also detected the molecular biological alterations of hidradenocarcinomas and found that both t (11;19) translocation and Her2/neu gene amplification were rare, the rate of p53 protein expression at the immunohistochemical level was high, and the frequency of TP53 mutations was relatively low [4]. Obaidat et al. [20] also reported some histological features of hidradenocarcinomas: hidradenocarcinoma cells exhibit obvious pleomorphism and an expansive lobular growth pattern accompanied by tubular differentiation, forming a large number of duct structures; the nucleus is monomorphic with high pigment and active mitosis; the cytoplasm is almost invisible, and tubular vacuoles can be seen in the cytoplasm when the tumour is necrotic.

Limited information about the clinical treatment and outcome of hidradenocarcinoma was mentioned in the literature, which contains few cases [11,15,21]. At present, early extensive surgical resection is still the first choice of treatment, but hidradenocarcinoma has an extremely obvious trend of recurrence and metastasis after extensive resection [21]. A study decades ago reported that after surgical resection, 50% of hidradenocarcinomas had local recurrence, and 60% of

### Table 3. Univariable survival analysis of hidradenocarcinoma patients.

| Variables         | Overall survival | Cancer-specific survival |
|-------------------|------------------|-------------------------|
|                   | HR (95%CI)       | P value                 | HR (95%CI)       | P value                 |
| Primary site      |                  |                         |                  |                         |
| Head and neck     | Reference        | 0.768 (0.499–1.182)     | 0.231            | Reference               |
| Trunk and limbs   | 0.739 (0.267–2.044) | .561                   |                  |                         |
| Gender            |                  |                         |                  |                         |
| Male              | Reference        | 0.981 (0.629–1.529)     | 0.933            | Reference               |
| Female            | 0.831 (0.283–2.436) | .736                   |                  |                         |
| Age               |                  |                         |                  |                         |
| 0–29 years        | Reference        | –                       | 0.909            | Reference               |
| 30–59 years       | –                | 0.893                   | –                | .931                   |
| ≥60 years         | –                | –                       | –                | .931                   |
| Race              |                  |                         |                  |                         |
| White             | Reference        | 0.892 (0.502–1.584)     | 0.697            | Reference               |
| Others            | 0.218 (0.758–6.495) | .146                   |                  |                         |
| Tumour size       |                  |                         |                  |                         |
| 1–10 mm           | Reference        | 1.62 (0.603–4.354)      | 0.339            | Reference               |
| 11–20 mm          | –                | 0.063                   | –                | .93                    |
| 21–30 mm          | 1.876 (0.657–5.36) | .24                    | –                | .952                   |
| 31–40 mm          | 3.282 (1.102–9.774) | 0.033                  | –                | .922                   |
| >50 mm            | 2.697 (2.434–16.289) | <0.001                | –                | .916                   |
| Unknown           | 2.027 (0.902–4.557) | 0.087                  | –                | .931                   |
| Grade             |                  |                         |                  |                         |
| I–II              | Reference        | 0.811 (0.342–1.92)      | 0.633            | 0.472 (0.055–4.054)     | .494 |
| III–IV            | 0.771 (0.463–1.284) | 0.771                  | 0.489 (0.163–1.461) | .2            |
| Unknown           | 1.044 (0.671–1.623) | 0.85                    | –                | .976                   |
| AJCC stage        |                  |                         |                  |                         |
| I–II              | Reference        | 0.629 (0.224–1.768)     | 0.379            | Reference               |
| III–IV            | 1.044 (0.671–1.623) | 0.85                    | –                | .976                   |
| Unknown           | Reference        | 1.975 (0.913–4.273)     | 0.084            | 1.244 (0.153–10.114)    | .839 |
| T stage           |                  |                         |                  |                         |
| T1–2              | Reference        | 1.192 (0.758–1.875)     | 0.447            | 0.976 (0.342–2.788)     | .964 |
| T3–4              | 0.255 (0.035–1.836) | 0.175                  | –                | .981                   |
| Unknown           | 0.805 (0.436–1.485) | 0.487                  | 0.748 (0.168–3.325) | .703                   |
| N stage           |                  |                         |                  |                         |
| N0                | Reference        | 0.417 (0.058–3.001)     | 0.385            | Reference               |
| N1–2              | 0.683 (0.314–1.482) | 0.335                  | 1.133 (0.255–5.039) | .87            |
| Unknown           | 0.738 (0.321–1.694) | 0.473                  | –                | .413                   |
| M stage           |                  |                         |                  |                         |
| M0                | Reference        | 0.344 (0.102–1.150)     | 0.05             | Reference               |
| M1                | 0.683 (0.314–1.482) | 0.335                  | 1.133 (0.255–5.039) | .87            |
| Unknown           | 0.738 (0.321–1.694) | 0.473                  | –                | .413                   |
| Surgery           |                  |                         |                  |                         |
| Performed         | Reference        | 0.344 (0.102–1.150)     | 0.05             | Reference               |
| Unperformed       | 0.683 (0.314–1.482) | 0.335                  | 1.133 (0.255–5.039) | .87            |

HR: hazard ratio; CI: confidence interval; AJCC: American Joint Committee on Cancer; T: Tumour; N: Node; M: Metastasis.
The diagnostic criteria and explore more prognostic factors. Second, there is a lack of information on tumour size, grade, AJCC stage, T stage in around 50% of patients. This shortcoming leads to a reduction in the actual sample size in the survival analysis of these clinicopathological variables.

**Conclusion**

Our research shows that hidradenocarcinoma is a malignant tumour with a good prognosis, which is different from previous views. Tumour size is inversely proportional to patients’ overall survival time, affecting the OS and CSS of patients. At the time of diagnosis, the tumour size of most patients is within 20 mm. This may also be one of the reasons for the good prognosis. Hidradenocarcinoma originates from the skin and is usually found at an early stage. However, because of the slow progress, some patients ignored it and...
missed the opportunity for early treatment. Therefore, improving health awareness, initial histological examination, and timely surgery are the keys to improving prognosis.

**Ethics approval and consent to participate**

This research was approved by the Ethical Committee of Soochow University and followed the guidelines outlined in the Declaration of Helsinki.

**Author contributions**

TG and RS were major contributors in writing the manuscript. RS designed the experiments, wrote the original draft and revised the manuscript. SP was responsible for planning, organising, checking the data and the manuscript throughout the project. All authors read and approved the final manuscript.

**Disclosure statement**

The authors declare that they have no competing interests.

**Funding**

The author(s) reported there is no funding associated with the work featured in this article.

**Data availability statement**

The datasets generated during the present study are available in the official software. SEER® Stat version 8.3.9.1 repository (https://seer.cancer.gov/data/).

**References**

[1] Keasbey LE, Hadley GG. Clearcell hidradenoma; report of three cases with widespread metastases. Cancer. 1954;7(5):934–952.

[2] Ohta M, Hiramoto M, Fuji M, et al. Nodular hidradenocarcinoma on the scalp of a young woman: case report and review of literature. Dermatol Surg. 2004;30(9):1265–1268.

[3] Mehregan AH, Hashimoto K, Rahbari H. Eccrine adenocarcinoma. A clinicopathologic study of 35 cases. Arch Dermatol. 1983;119(2):104–114.

[4] Kazakov DV, Ivan D, Kutzner H, et al. Cutaneous hidradenocarcinoma: a clinicopathological, immunohistochemical, and molecular biologic study of 14 cases, including Her2/neu gene expression/amplification, TP53 gene mutation analysis, and t(11;19) translocation. Am J Dermatopathol. 2009;31(3):236–247.

[5] Nandeesh BN, Rajalakshmi T. A study of histopathologic spectrum of nodular hidradenoma. Am J Dermatopathol. 2012;34(5):461–470.

[6] Toulemonde A, Croue A, Rodien P, et al. Malignant nodular hidradenoma and multiple nodular hidradenomas in a hypogonadic patient. Annales de Dermatologie et de Venereologie. 2006;133(12):1005–1008.

[7] Paranjothi M, Mukunda A. Clear cell hidradenoma: an unusual tumor of the oral cavity. J Oral Maxillofac Pathol. 2013;17(1):136–138.

[8] Wong TY, Suster S, Nogita T, et al. Clear cell eccrine carcinomas of the skin. A clinicopathologic study of nine patients. Cancer. 1994;73(6):1631–1643.

[9] Headington JT, Niederhuber JE, Beals TF. Malignant clear cell acrospiroma. Cancer. 1978;41(2):641–647.

[10] Mambo NC. The significance of atypical nuclear changes in benign eccrine acrospiromas: a clinical and pathological study of 18 cases. J Cutan Pathol. 1984;11(1):35–44.

[11] Stout AP, Cooley SG. Carcinoma of sweat glands. Cancer. 1951;4(3):521–536.

[12] Wu H, Elenitsas R. Malignant nodular hidradenoma in a patient with neurofibromatosis type 1: a case report and review of the literature. Cutis. 2001;68(4):273–278.

[13] Sajithkumar VI, Mandai S, Rathore PK. Malignant nodular hidradenoma of nose. Indian J Otolaryngol Head Neck Surg. 1999;51(1):76–77.

[14] Maiti T, Somanna S, Devi BI, et al. Malignant nodular hidradenocarcinoma of scalp. J Neurosci Rural Pract. 2014;5(4):423–425.

[15] Souvatzidis P, Sbano P, Mandato F, et al. Malignant nodular hidradenoma of the skin: report of seven cases. J Eur Acad Dermatol Venereol. 2008;22(5):549–554.

[16] Nazarian RM, Kapur P, Rakheja D, et al. Atypical and malignant hidradenomas: a histological and immunohistochemical study. Mod Pathol. 2009;22(4):600–610.

[17] Hernandez-Perez E, Cestoni-Parducci R. Nodular hidradenocarcinoma. A 10-year review. J Am Acad Dermatol. 1985;12(1 Pt 1):15–20.

[18] Greiner M, Pfeiffer D, Smith RD. Principles and practical application of the receiver-operating characteristic analysis for diagnostic tests. Prev Vet Med. 2000;45(1–2):23–41.

[19] Ko CJ, Cochran AJ, Eng W, et al. Hidradenocarcinoma: a histological and immunohistochemical study. J Cutan Pathol. 2006;33(11):726–730.

[20] Obaidat NA, Alsaad KO, Ghazarian D. Skin adnexal neoplasms-part 2: an approach to tumours of cutaneous sweat glands. J Clin Pathol. 2007;60(2):145–159.

[21] Garcia-Bonafe MM, Campins MM, Redecilla PH. Malignant hidradenocarcinoma on the scalp: report of a case with fine needle aspiration cytology features and histologic correlation. Acta Cytol. 2009;53(5):576–580.

[22] Orlandi RR, Sercarz JA, Doberneck SA, et al. Malignant clear cell hidradenoma of the upper lip. Head Neck. 1994;16(5):443–449.

[23] Messing MJ, Richardson MS, Smith MT, et al. Metastatic clear-cell hidradenocarcinoma of the vulva. Gynecol Oncol. 1993;48(2):264–268.
[24] Long WP, Dupin C, Levine EA. Recurrent malignant acrospiroma. Treatment by chest wall excision. Dermatol Surg. 1998;24(8):908–912. discussion 911–2.

[25] Jouary T, Kaiafa A, Lipinski P, et al. Metastatic hidradenocarcinoma: efficacy of capecitabine. Arch Dermatol. 2006;142(10):1366–1367.

[26] Tolland JP, Brenn T, Guldbakke KK, et al. Mohs micrographic surgery, sentinel lymph node mapping, and estrogen receptor analysis for the treatment of malignant nodular hidradenoma. Dermatol Surg. 2006;32(10):1294–1301.